Cencora, Inc. (COR)
(Delayed Data from NYSE)
$237.43 USD
+1.79 (0.76%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $237.58 +0.15 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.43 USD
+1.79 (0.76%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $237.58 +0.15 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford
by Zacks Equity Research
GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.
UnitedHealth (UNH) Faces Investigation Following Cyberattack
by Zacks Equity Research
A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.
Reasons to Add Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Revvity's (RVTY) New Launch to Boost Research Productivity
by Zacks Equity Research
Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA
by Zacks Equity Research
Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.
HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System
by Zacks Equity Research
Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
Align Technology (ALGN) Gains From Innovation, Macro Issues Ail
by Zacks Equity Research
In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.
Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100
by Zacks Equity Research
The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).
Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery
by Zacks Equity Research
Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
Here's Why You Should Retain HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) strength in HSAs raises optimism about the stock.
Cencora (COR) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add Masimo (MASI) to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Here's Why You Should Retain Inspire Medical (INSP) Stock Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
by Zacks Equity Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio
by Zacks Equity Research
High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
Labcorp (LH) Presents New Research on Precision Diagnostics
by Zacks Equity Research
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.
Charles River (CRL) Extends Gene Therapy Offering With New Pact
by Zacks Equity Research
Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.